Tue, Oct 21, 2014, 12:03 AM EDT - U.S. Markets open in 9 hrs 27 mins


% | $
Quotes you view appear here for quick access.

Alnylam Pharmaceuticals, Inc. Message Board

tnk.shorting 6 posts  |  Last Activity: Oct 3, 2014 7:56 PM Member since: Feb 29, 2012
SortNewest  |  Oldest  |  Highest Rated Expand all messages
  • tnk.shorting tnk.shorting Oct 3, 2014 5:36 PM Flag

    I'm scratching my head as I try to reconcile what management publicly stated on the 8/7/2014 conference call with the anti-climactic ESMO abstract, Is more information forthcoming? Following is my transcription of the SYNERGY-relevant portions of the conference call. Can anyone corroborate Cormack's statements?

  • tnk.shorting tnk.shorting Oct 3, 2014 5:38 PM Flag

    Chad Messer: "Alright, great, thanks, [I'll] look forward to seeing that data."

    Cormack: "Yeah, it'll be an exciting presentation, and we'd love to do some follow up, obviously, after that data that is available [is] in the public domain, and be able to speak to it."

  • tnk.shorting by tnk.shorting Oct 3, 2014 5:41 PM Flag

    I posted Cormack's statements in another thread, but, for some reason, Yahoo didn't let them stick. Trying again:

    Cormack's prepared statement on conference call:

    Final data from the Phase 3 SYNERGY trial will be presented next month at the ESMO conference. Over the past several months, we have been working closely with investigators to thoroughly understand these results, Our subsequent exploratory analysis suggests that patients in the SYNERGY trial who had the worst poor-prognostic factors and received custirsen treatment appeared to have lived longer. This supports our belief in evaluating custirsen in patients who typically have a poor prognosis and are exposed to more treatments prior to treatment with custirsen such as patients in the second-line chemotherapy CRPC AFFINITY trial.

  • Reply to

    August 7 Conference Call

    by tnk.shorting Oct 3, 2014 5:41 PM
    tnk.shorting tnk.shorting Oct 3, 2014 5:42 PM Flag

    Cormack's statements during the Q&A:

    Operator: "Our next question comes from Chad Messer, with Needham. Your line is now open."

    Chad Messer (Needham): Great, thanks for taking my question. Scott, you mentioned that - and I know we'll get final data at a presentation at ESMO - but that worse patients in SYNERGY appeared to live longer, and I presume you mean in custirsen-treated versus the control arm. Is there anything you can share now about what constituted 'worse' in that statement?

  • Reply to

    August 7 Conference Call

    by tnk.shorting Oct 3, 2014 5:41 PM
    tnk.shorting tnk.shorting Oct 3, 2014 5:44 PM Flag

    So, my question is, is there more info coming down the pike?

  • tnk.shorting tnk.shorting Oct 3, 2014 7:56 PM Flag

    Only shares Cormack sold were for withholding taxes on stock options. But Cormack is a liar - just like you. I gave up trying to post my transcript of the conference call since Yahoo censors won't let it in for some reason. However, anyone who listened to the cc was promised an "exciting presentation" at ESMO with details about how sicker patients " did, in fact, live longer on custirsen as we talked about in the prepared statement." As the PPS shows, the ESMO abstract did not corroborate Cormack's representations. Played again..

    For those who don't frequent the ISIS board, you and your many aliases are Darkster, and, no, you never posted any messages about selling OGXI at $22. Not sure who's the bigger liar: you or Cormack.

87.99+1.81(+2.10%)Oct 20 4:00 PMEDT

Trending Tickers

Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.